CN102166199A - 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法 - Google Patents
一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法 Download PDFInfo
- Publication number
- CN102166199A CN102166199A CN 201110083301 CN201110083301A CN102166199A CN 102166199 A CN102166199 A CN 102166199A CN 201110083301 CN201110083301 CN 201110083301 CN 201110083301 A CN201110083301 A CN 201110083301A CN 102166199 A CN102166199 A CN 102166199A
- Authority
- CN
- China
- Prior art keywords
- freeze
- temperature
- smooth
- hours
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 26
- 239000007924 injection Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- VRQHBYGYXDWZDL-OOZCZQCLSA-N fosaprepitant dimeglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NN(P(O)(O)=O)C(=O)N1 VRQHBYGYXDWZDL-OOZCZQCLSA-N 0.000 title abstract description 5
- 229940044880 fosaprepitant dimeglumine Drugs 0.000 title abstract description 5
- 230000008014 freezing Effects 0.000 claims abstract description 17
- 238000007710 freezing Methods 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 60
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 13
- 229960003194 meglumine Drugs 0.000 claims description 13
- 238000004821 distillation Methods 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- 239000007789 gas Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 abstract 3
- 238000001816 cooling Methods 0.000 abstract 2
- 229910001873 dinitrogen Inorganic materials 0.000 abstract 1
- 230000010355 oscillation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 3
- 229960001372 aprepitant Drugs 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002895 emetic Substances 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 206010009866 Cold sweat Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
外观 | 复溶速度(s) | 澄清度 | 合格率 | |
实施例1所制产品 | 疏松饱满 | 5 | <1号 | 98% |
实施例2所制产品 | 疏松饱满 | 9 | <1号 | 97% |
实施例3所制产品 | 疏松饱满 | 7 | <1号 | 98% |
常规技术所制产品 | 萎缩塌陷 | 25 | 2号或>2号 | 38% |
外观 | 复溶速度(s) | 澄清度 | 合格率 | |
实施例1所制产品 | 疏松饱满 | 5 | <1号 | 98% |
实施例2所制产品 | 疏松饱满 | 8 | 1号 | 96% |
实施例3所制产品 | 疏松饱满 | 10 | 1号 | 96% |
常规技术所制产品 | 萎缩塌陷 | 40 | >2号 | 22% |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100833011A CN102166199B (zh) | 2011-04-02 | 2011-04-02 | 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100833011A CN102166199B (zh) | 2011-04-02 | 2011-04-02 | 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102166199A true CN102166199A (zh) | 2011-08-31 |
CN102166199B CN102166199B (zh) | 2012-11-07 |
Family
ID=44487644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100833011A Expired - Fee Related CN102166199B (zh) | 2011-04-02 | 2011-04-02 | 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102166199B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103156813A (zh) * | 2013-03-29 | 2013-06-19 | 山东罗欣药业股份有限公司 | 福沙吡坦二甲葡胺注射剂组合物及其制备方法 |
CN103565760A (zh) * | 2013-11-18 | 2014-02-12 | 南京艾德凯腾生物医药有限责任公司 | 一种福沙匹坦二甲葡胺冻干粉及制备方法 |
CN104042572A (zh) * | 2013-03-12 | 2014-09-17 | 江苏奥赛康药业股份有限公司 | 一种含福沙匹坦二甲葡胺的注射用组合物及其制备方法 |
CN104414983A (zh) * | 2013-08-28 | 2015-03-18 | 山东新时代药业有限公司 | 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺 |
CN104414980A (zh) * | 2013-08-22 | 2015-03-18 | 成都苑东药业有限公司 | 一种注射用福沙匹坦二甲葡胺组合物及其制备方法 |
CN107595787A (zh) * | 2017-09-27 | 2018-01-19 | 山东省药学科学院 | 一种注射用福沙匹坦双葡甲胺冻干制剂的制备方法 |
CN111351318A (zh) * | 2020-03-07 | 2020-06-30 | 苏州德沃生物技术有限公司 | 抗体偶联乳胶的冻干方法 |
US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
CN114526580A (zh) * | 2022-03-25 | 2022-05-24 | 上海工程技术大学 | 用于组织工程的梯度降温冷冻干燥方法 |
CN116763744A (zh) * | 2023-07-20 | 2023-09-19 | 石家庄四药有限公司 | 一种注射用氯诺昔康的冻干工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101056672A (zh) * | 2004-11-05 | 2007-10-17 | 默克公司 | 制备{3-[2(r)-[(1r)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3(s)-(4-氟苯基)吗啉-4-基 ]甲基]-5-氧代-4,5-二氢-[1,2,4]-三唑-1-基}膦酸的方法 |
CA2730681A1 (en) * | 2008-07-17 | 2010-02-18 | Glenmark Generics Limited | Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations |
-
2011
- 2011-04-02 CN CN2011100833011A patent/CN102166199B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101056672A (zh) * | 2004-11-05 | 2007-10-17 | 默克公司 | 制备{3-[2(r)-[(1r)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3(s)-(4-氟苯基)吗啉-4-基 ]甲基]-5-氧代-4,5-二氢-[1,2,4]-三唑-1-基}膦酸的方法 |
CA2730681A1 (en) * | 2008-07-17 | 2010-02-18 | Glenmark Generics Limited | Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042572B (zh) * | 2013-03-12 | 2016-04-06 | 江苏奥赛康药业股份有限公司 | 一种含福沙匹坦二甲葡胺的注射用组合物及其制备方法 |
CN104042572A (zh) * | 2013-03-12 | 2014-09-17 | 江苏奥赛康药业股份有限公司 | 一种含福沙匹坦二甲葡胺的注射用组合物及其制备方法 |
CN103156813A (zh) * | 2013-03-29 | 2013-06-19 | 山东罗欣药业股份有限公司 | 福沙吡坦二甲葡胺注射剂组合物及其制备方法 |
CN104414980B (zh) * | 2013-08-22 | 2017-03-29 | 成都苑东生物制药股份有限公司 | 一种注射用福沙匹坦二甲葡胺组合物及其制备方法 |
CN104414980A (zh) * | 2013-08-22 | 2015-03-18 | 成都苑东药业有限公司 | 一种注射用福沙匹坦二甲葡胺组合物及其制备方法 |
CN104414983A (zh) * | 2013-08-28 | 2015-03-18 | 山东新时代药业有限公司 | 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺 |
CN104414983B (zh) * | 2013-08-28 | 2018-09-04 | 山东新时代药业有限公司 | 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺 |
CN103565760A (zh) * | 2013-11-18 | 2014-02-12 | 南京艾德凯腾生物医药有限责任公司 | 一种福沙匹坦二甲葡胺冻干粉及制备方法 |
CN107595787A (zh) * | 2017-09-27 | 2018-01-19 | 山东省药学科学院 | 一种注射用福沙匹坦双葡甲胺冻干制剂的制备方法 |
US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
CN111351318A (zh) * | 2020-03-07 | 2020-06-30 | 苏州德沃生物技术有限公司 | 抗体偶联乳胶的冻干方法 |
CN114526580A (zh) * | 2022-03-25 | 2022-05-24 | 上海工程技术大学 | 用于组织工程的梯度降温冷冻干燥方法 |
CN116763744A (zh) * | 2023-07-20 | 2023-09-19 | 石家庄四药有限公司 | 一种注射用氯诺昔康的冻干工艺 |
CN116763744B (zh) * | 2023-07-20 | 2024-03-08 | 石家庄四药有限公司 | 一种注射用氯诺昔康的冻干工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN102166199B (zh) | 2012-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102166199B (zh) | 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法 | |
JP5755367B2 (ja) | 圧力差による氷霧の分散を用いた凍結乾燥サイクルの冷凍工程における核形成の制御 | |
AU2014368994B2 (en) | Compositions and methods for atmospheric spray freeze drying | |
CN104302995B (zh) | 在冻干循环的冷冻过程中利用来自冷凝霜的压差冰晶分布的受控成核的方法 | |
CN107772531B (zh) | 一种植物多糖基气凝胶香烟过滤嘴的制造工艺及装备 | |
CN101897672A (zh) | 一种注射用阿昔洛韦冻干制剂的制备方法 | |
JPS6143356B2 (zh) | ||
CN102415949A (zh) | 一种新型药液灌装冷冻工艺及药液灌装冷冻设备 | |
CN1994461A (zh) | 一种制备注射用还原型谷胱甘肽的冻干工艺 | |
CN104666303B (zh) | 一种注射用更昔洛韦的冷冻干燥工艺 | |
CN110693821A (zh) | 一种制备注射用制备注射用泮托拉唑钠的方法 | |
CN102058548B (zh) | 一种供注射用的盐酸氨溴索组合物及其制备方法 | |
CN106749332B (zh) | 氨苄西林钠晶体的生产工艺 | |
CN102125550B (zh) | 一种供注射用的盐酸昂丹司琼组合物及其制备方法 | |
CN101723957B (zh) | 一种氨苄西林钠盐的制备方法 | |
CN106727364B (zh) | 一种注射用氯诺昔康的冻干工艺 | |
CN104173299A (zh) | 一种注射用盐酸川芎嗪的冷冻干燥方法 | |
CN113730360A (zh) | 一种制备辅酶a的冻干方法 | |
CN109364030B (zh) | 一种注射用硼替佐米冻干粉针及其制备工艺 | |
CN108175750A (zh) | 一种注射用阿奇霉素的冷冻干燥方法 | |
CN104352451A (zh) | 一种注射用奥扎格雷钠冻干粉及其制备方法 | |
CN110613688A (zh) | 一种制备更昔洛韦的冻干方法 | |
CN102920671A (zh) | 注射用头孢美唑钠 | |
CN105055340A (zh) | 制备氨甲环酸冻干粉针剂的工艺配方和方法 | |
CN105434368A (zh) | 一种注射用还原型谷胱甘肽及其预冻方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Jie Document name: Notification to Pay the Fees |
|
ASS | Succession or assignment of patent right |
Owner name: WUHAN XIANLU PHARMACEUTICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WUHAN XIXI BIOTECHNOLOGY CO., LTD. Effective date: 20130705 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430071 WUHAN, HUBEI PROVINCE TO: 430064 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130705 Address after: 430064 South Lake Road, Hongshan District, Hubei, China, No. 8, No. Patentee after: Wuhan Xianlu Medical Technology Co., Ltd. Address before: 430071, E-3-101, room 88, Xu Dong Avenue, Wuhan, Wuchang, Hubei Patentee before: Wuhan Xixi Biotechnology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121107 Termination date: 20210402 |
|
CF01 | Termination of patent right due to non-payment of annual fee |